Stock comparison
Bruker Corporation 6.375% Mandatory Convertible Preferred Stock, Series A
ResMed
Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.
BRKRP
Bruker Corporation 6.375% Mandatory Convertible Preferred Stock, Series A
Market cap
$53.05B
Sector
Healthcare
RMD
ResMed
Market cap
$30.18B
Sector
Healthcare
Overall winner
ResMed RMD
Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.
Fit scores by strategy
| Strategy | BRKRP | RMD | Winner |
|---|---|---|---|
| Warren Buffett | 38D | 72B | RMD |
| Benjamin Graham | 45D | 75B | RMD |
| Philip Fisher |
Side-by-side metrics
| Metric | BRKRP | RMD |
|---|---|---|
| Market cap | $53.05B | $30.18B |
| P/E (TTM) | - | 19.6x |
| EV/EBIT | 59.6x | 17.1x |
| ROIC (TTM) | -2.92% | 19.63% |
| Gross margin | 45.56% | 61.69% |
| Net margin | -0.34% | 27.44% |
| Revenue CAGR 5y | 9.19% |
Where each one wins
The metrics with the biggest gap between the two - sorted so the most decisive edges read first.
BRKRP leads on
- P/E (TTM)-vs 19.6x+103%
- Market cap$53.05Bvs $30.18B+43%
RMD leads on
- ROIC (TTM)19.63%vs -2.92%+115%
More like RMD
Related on invest-like
Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.